Impedimed Stock Current Valuation
| IPD Stock | 0.05 0 2.00% |
Valuation analysis of Impedimed helps investors to measure Impedimed's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Impedimed's Cash is comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 28.3 M in 2024, whereas Free Cash Flow is likely to drop (21.9 M) in 2024. Fundamental drivers impacting Impedimed's valuation include:
Price Book 2.533 | Enterprise Value 79.7 M | Enterprise Value Ebitda (9.34) | Price Sales 10.0011 | Enterprise Value Revenue 7.9292 |
Overvalued
Today
Please note that Impedimed's price fluctuation is out of control at this time. Calculation of the real value of Impedimed is based on 3 months time horizon. Increasing Impedimed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Impedimed's intrinsic value may or may not be the same as its current market price of 0.05, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.051 | Real 0.0445 | Hype 0.05 | Naive 0.049 |
The intrinsic value of Impedimed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Impedimed's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Impedimed helps investors to forecast how Impedimed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Impedimed more accurately as focusing exclusively on Impedimed's fundamentals will not take into account other important factors: Impedimed Company Current Valuation Analysis
Impedimed's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Impedimed Current Valuation | 79.71 M |
Most of Impedimed's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Impedimed is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Impedimed has a Current Valuation of 79.71 M. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current valuation for all Australia stocks is notably lower than that of the firm.
Impedimed Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Impedimed's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Impedimed could also be used in its relative valuation, which is a method of valuing Impedimed by comparing valuation metrics of similar companies.Impedimed is currently under evaluation in current valuation category among its peers.
Impedimed Fundamentals
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.92) % | ||||
| Operating Margin | (2.01) % | ||||
| Current Valuation | 79.71 M | ||||
| Shares Outstanding | 2.02 B | ||||
| Shares Owned By Insiders | 9.13 % | ||||
| Shares Owned By Institutions | 16.29 % | ||||
| Price To Book | 2.53 X | ||||
| Price To Sales | 10.00 X | ||||
| Revenue | 10.32 M | ||||
| Gross Profit | 9.8 M | ||||
| EBITDA | (22.05 M) | ||||
| Net Income | (19.79 M) | ||||
| Cash And Equivalents | 13.55 M | ||||
| Total Debt | 1.14 M | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (17.79 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 0.15 | ||||
| Number Of Employees | 83 | ||||
| Beta | 2.87 | ||||
| Market Capitalization | 103.2 M | ||||
| Total Asset | 46.99 M | ||||
| Retained Earnings | (330.95 M) | ||||
| Working Capital | 24.8 M | ||||
| Net Asset | 46.99 M |
About Impedimed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Impedimed's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Impedimed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Impedimed based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Impedimed Stock Analysis
When running Impedimed's price analysis, check to measure Impedimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Impedimed is operating at the current time. Most of Impedimed's value examination focuses on studying past and present price action to predict the probability of Impedimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Impedimed's price. Additionally, you may evaluate how the addition of Impedimed to your portfolios can decrease your overall portfolio volatility.